Faculty: Charles Paul | Code: FDB1607
Advanced therapies have created a manufacturing environment where product quality, patient safety, traceability, and operational execution are inseparably linked. Unlike traditional manufacturing models, advanced therapy operations frequently involve patient-specific starting materials, individualized manufacturing processes, multiple external partners, complex logistics networks, and compressed timelines that demand extraordinary levels of process control.
This webinar examines the critical GMP systems required to maintain chain-of-identity and support compliant product release within advanced therapy manufacturing environments. Participants will explore how patient-specific materials are controlled throughout collection, transportation, manufacturing, testing, storage, shipment, and administration activities. The session emphasizes practical implementation strategies that support both regulatory compliance and operational execution.
Participants will learn how chain-of-identity systems extend beyond labeling and documentation requirements to encompass workflow design, electronic systems, material handling procedures, supplier management, transportation controls, and release governance. The webinar will address common operational failure points that can compromise traceability and examine approaches for reducing risk through system design, procedural controls, training, and oversight mechanisms.
The session will also explore GMP release considerations unique to advanced therapies, including conditional release decisions, rapid testing strategies, comparability assessments, product disposition management, deviation handling, change control considerations, and quality oversight of outsourced activities. Special attention will be given to balancing patient treatment timelines with product quality requirements and regulatory expectations.
Participants will further examine regulatory expectations from FDA, EMA, and global health authorities regarding traceability, chain-of-custody documentation, quality agreements, data integrity, supplier oversight, and inspection readiness. Real-world operational challenges associated with scaling advanced therapy programs from clinical manufacturing to commercial production will also be discussed.
By the conclusion of the webinar, attendees will understand how to establish effective chain-of-identity controls, strengthen release decision processes, improve traceability systems, and build quality infrastructures capable of supporting increasingly complex advanced therapy manufacturing operations while protecting both patient safety and regulatory compliance.
Advanced therapies introduce quality and operational challenges unlike those encountered in traditional pharmaceutical manufacturing. In many cases, there is no opportunity to replace a batch, repeat a manufacturing campaign, or recover from a significant process error. The product may represent a single patient's treatment opportunity, making quality decisions and traceability controls critically important.
Regulators continue to increase their scrutiny of chain-of-identity, chain-of-custody, traceability, release processes, data integrity controls, and supplier oversight within advanced therapy manufacturing operations. Organizations must demonstrate that they can maintain complete control over patient-specific materials from collection through final administration while ensuring that every critical quality decision is fully documented and scientifically justified.
Many organizations struggle with integrating traditional GMP systems into advanced therapy workflows. Issues involving labeling controls, material transfers, electronic tracking systems, sample management, release coordination, transportation controls, outsourced activities, and patient scheduling can create operational vulnerabilities that may not be immediately apparent. These challenges become even more significant as organizations move from clinical production into commercial manufacturing environments.
This webinar provides practical guidance for establishing robust chain-of-identity systems, managing GMP release activities, implementing traceability controls, and reducing operational risk within advanced therapy manufacturing. Participants will learn how regulatory expectations translate into daily operational requirements and how organizations can build sustainable systems capable of supporting both compliance and patient safety. Whether involved in cell therapy, gene therapy, tissue engineering, personalized medicine, or related advanced therapy programs, attendees will gain practical strategies that can be immediately applied within their organizations.
Advanced therapy medicinal products (ATMPs), including cell therapies, gene therapies, tissue-engineered products, and personalized medicines, have fundamentally changed the traditional manufacturing and quality paradigm. Unlike conventional pharmaceutical products produced in large batches for broad patient populations, many advanced therapies are manufactured for specific individuals, often involving complex collection, processing, testing, release, and administration activities that must be precisely coordinated across multiple organizations and locations.
In these environments, maintaining chain-of-identity and chain-of-custody controls becomes as critical as the manufacturing process itself. A single breakdown in patient identification, material tracking, labeling, documentation, transportation, or release decision-making can create significant patient safety, product quality, regulatory, and business risks. Regulatory agencies worldwide have increasingly focused on the controls organizations use to ensure that the right product reaches the right patient at the right time while maintaining complete traceability throughout the product lifecycle.
The operational challenges are substantial. Organizations must manage complex logistics, compressed manufacturing timelines, limited material availability, multiple handoffs, outsourced testing, evolving technologies, and highly individualized production processes. Traditional GMP systems often require modification to support these unique operational realities.
This webinar examines the GMP release requirements, chain-of-identity controls, traceability systems, and operational practices necessary to support advanced therapy manufacturing and patient delivery. Participants will gain practical insight into building systems that maintain product integrity, patient safety, regulatory compliance, and operational reliability across increasingly complex advanced therapy supply chains.
Charles H. Paul is President of CHP Consulting LLC, a regulatory compliance, operational excellence, training, and technical documentation consulting firm supporting pharmaceutical, biotechnology, medical device, and advanced therapy organizations worldwide. With more than 30 years of experience in regulated manufacturing environments, Charles specializes in helping organizations build sustainable quality systems that support compliance, operational performance, workforce effectiveness, and inspection readiness.
His experience includes GMP quality systems, manufacturing operations, technical training development, process validation, deviation management, CAPA systems, operational excellence, documentation systems, and regulatory inspection preparation. Charles has supported organizations implementing new technologies, expanding manufacturing operations, establishing quality infrastructures, and preparing for complex regulatory inspections.
As advanced therapies continue to transform healthcare and manufacturing models, Charles brings a practical operational perspective to the unique challenges associated with traceability, quality oversight, patient-specific manufacturing, and regulatory compliance. His presentations focus on translating regulatory expectations into effective operational practices that support both product quality and business success.
Charles is a recognized author, speaker, and consultant who has delivered numerous webinars and seminars on GMP compliance, quality systems, human performance improvement, technical documentation, inspection readiness, and operational excellence throughout the life sciences industry.